We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EPD:NYSEEnterprise Products Partners L.P. Analysis

Data as of 2026-07-18 - not real-time

$38.20

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Enterprise Products Partners is trading at $38.2, comfortably above its 20‑day ($37.13), 50‑day ($37.64) and 200‑day ($35.01) moving averages, indicating a short‑term bullish bias. The MACD histogram is positive (0.17) and the signal line is below the MACD line, reinforcing the bullish momentum, while the RSI sits at 57, suggesting room for upside without overbought pressure. Support sits at $36.07 and resistance at $38.50, placing the stock near the top of its current range. The 30‑day volatility of roughly 21% and a computed beta of –0.19 point to modest price swings and a slight inverse correlation to the broader market. The Fear & Greed Index reads 87.9, classifying market sentiment as “Extreme Greed,” and the model estimates an 8% upside to a target of $41.3. These technical signals align with a market environment that is currently favorable for price appreciation.
Fundamentally, EPD trades at a forward P/E of 12.2 versus an industry average of 21.4, positioning it as undervalued on earnings multiples, while the dividend yield of 5.8% and a payout ratio of 80% offer attractive income. However, the balance sheet is leveraged, with a debt‑to‑equity of 113% and free cash flow of only $156 M against substantial dividend commitments, raising questions about long‑term dividend sustainability. Operating margins of ~12% and a ROE near 20% demonstrate solid profitability, but revenue is contracting at –6.7% YoY. Given the stable cash‑flow profile of midstream contracts, the company can likely maintain distributions in the near term, yet the high leverage and modest free cash flow suggest caution. Overall, the blend of undervalued valuation, strong yield, and manageable technical risk supports a cautious but positive outlook.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near resistance
  • bullish MACD
  • high dividend yield

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • undervalued P/E vs industry
  • attractive dividend yield
  • stable midstream contracts

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • long‑term demand for midstream services
  • solid ROE
  • reasonable valuation cushion

Key Metrics & Analysis

Financial Health

Revenue Growth-6.70%
Profit Margin11.45%
P/E Ratio14.1
ROE19.82%
ROA5.69%
Debt/Equity113.13
P/B Ratio2.8
Op. Cash Flow$7.7B
Free Cash Flow$155.9M
Industry P/E21.4

Technical Analysis

TrendNeutral
RSI57.5
Support$36.07
Resistance$38.50
MA 20$37.13
MA 50$37.64
MA 200$35.01
MACDBullish
VolumeStable
Fear & Greed Index87.91

Valuation

Target Price$41.30
Upside/Downside8.12%
GradeUndervalued
TypeValue
Dividend Yield5.80%

Risk Assessment

Beta-0.19
Volatility21.47%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.